References:
Phase II study of imatinib mesylate as therapy for patients with systemic mastocytosis. AU. Vega-Ruiz A, Cortes JE, Sever M, Manshouri T, Quintás-Cardama A, Luthra R, Kantarjian HM, Verstovsek S SO. Leuk Res. 2009;33(11):1481. Epub 2009 Feb 3.
A precision therapy against cancers driven by KIT/PDGFRA mutations. AU Evans EK, Gardino AK, Kim JL, Hodous BL, Shutes A, Davis A, Zhu XJ, Schmidt-Kittler O, Wilson D, Wilson K, DiPietro L, Zhang Y, Brooijmans N, LaBranche TP, Wozniak A, Gebreyohannes YK, Schöffski P, Heinrich MC, DeAngelo DJ, Miller S, Wolf B, Kohl N, Guzi T, Lydon N, Boral A, Lengauer C SO. Sci Transl Med. 2017;9(414)
DeAngelo, D.J., Radia, D.H., George, T.I. et al.  Safety and efficacy of avapritinib in advanced systemic mastocytosis: the phase 1 EXPLORER trial. Nat Med  27 , 2183–2191 (2021). https://doi.org/10.1038/s41591-021-01538-9
van Anrooij B, Oude Elberink JNG, Span LFR, de Monchy JGR, Rosati S, Mulder AB, Kluin-Nelemans JC. Midostaurin in patients with indolent systemic mastocytosis: An open-label phase 2 trial. J Allergy Clin Immunol. 2018 Sep;142(3):1006-1008.e7. doi: 10.1016/j.jaci.2018.06.003. Epub 2018 Jun 8. PMID: 29890238.
WHO Classification of Tumours of Haematopoietic and Lymphoid Tissues, revised 4th edition, Swerdlow SH, Campo E, Harris NL, et al. (Eds), International Agency for Research on Cancer (IARC), Lyon 2017.
Pardanani A. Systemic mastocytosis in adults: 2021 Update on diagnosis, risk stratification and management. Am J Hematol. 2021 Apr 1;96(4):508-525. doi: 10.1002/ajh.26118. Epub 2021 Feb 21. PMID: 33524167.
Akin C., Elberink H.O., Gotlib J., Sabato V., Hartmann K., Broesby-Olsen S., Castells M., Tashi T., Heaney M.L., George T.I., et al. Pioneer Part 2: A Randomized, Double-Blind, Placebo-Controlled, Phase 2 Study to Evaluate Safety and Efficacy of Avapritinib in Indolent Systemic Mastocytosis. Blood. 2020;136:41–42. doi: 10.1182/blood-2020-136632.